[Dysmenorrhea in the female adolescent. Clinical, biological and therapeutic data].
The physiology and pathology of dysmenorrhea in adolescent girls has become clear in the past 5 years. Although the prime cause of the disorder has not been identified, the obvious rise in PGF2 alpha prostaglandins is an objective biologic sign. As a result, more specific treatment has become possible with more definite and established care of this "condition" which is often distressing to the teenage girl affected.
D000293:Adolescent; D015237:Dinoprost; D004412:Dysmenorrhea / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D005602:France; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D011460:Prostaglandins F / Q000097:blood; D014481:United States; D062367:ortho-Aminobenzoates / Q000627:therapeutic use
D011448:Prostaglandin Antagonists; D011460:Prostaglandins F; D062367:ortho-Aminobenzoates; C001209:fenamic acid; D015237:Dinoprost; D007052:Ibuprofen; D007213:Indomethacin
Dysménorrhée de l'adolescente. Données cliniques, biologiques et thérapeutiques.